New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
07:39 EDTFOLDAmicus Therapeutics announces 3-in-3 strategy for the next generation ERTs
Amicus Therapeutics provided its FY14 strategic outlook and financial guidance. Key Highlights include: Amicus announces "3-in-3" strategy for three next-generation Enzyme Replacement Therapies, or ERTs, expected to enter the clinic in next three years with lead programs in Fabry, Pompe and Mucopolysaccharidosis I; preclinical proof-of-concept data for next-generation ERTs for Fabry and Pompe to be featured at Lysosomal Disease Network WORLD Symposium and American College of Medical Genetics meetings in 1H14; data from global registration studies of migalastat HCl monotherapy for Fabry disease expected to include complete 12- and 24-month data from Study 011 in 2Q14 and 18-month clinical data from Study 012 in 2H14. Company also stated "As we enter 2014, Amicus is strongly positioned to continue our focus on advancing a pipeline of next-generation enzyme replacement therapies for patients with lysosomal storage diseases. "
News For FOLD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 15, 2015
06:09 EDTFOLDAmicus Therapeutics promotes Bradley Campbell to President and COO
Subscribe for More Information
January 12, 2015
07:49 EDTFOLDAmicus Therapeutics sees current cash to fund operations into 2017
Amicus Therapeutics provided its full-year 2015 strategic outlook and financial guidance. The company sees its FY15 net cash spend expected to range between $73M-$83M. Current cash of $169.1M at December 31, 2014 is projected to fund operating plan into 2017. Amicus said migalastat monotherapy FDA interaction is planned in 1Q15 and an MAA submission is on track for mid-2015 to seek marketing approval for Fabry patients with amenable mutations. Initiation of longer-term Phase 2 Fabry co-administration study is anticipated in 2015 in support of Fabry franchise strategy to develop migalastat in combination with ERT for Fabry patients with non-amenable mutations. Next-generation Pompe ERT is set to enter clinic in 2H15 and additional details on Pompe program are to be highlighted at 33rd Annual J.P. Morgan Healthcare Conference, the company said.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use